Lung Cancer

The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.

An expert discusses lung cancer advances from 2020, as well as exciting new research that is underway.

Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for potential molecular drivers of their disease, explained Nathan Pennell, MD, PhD.

The FDA has approved 2 abbreviated new drug applications (ANDAs) for everolimus (Afinitor) tablets for the treatment of patients numerous malignancies.

The FDA has approved atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) for the first-line treatment of adult patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR or ALK molecular aberrations.

The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1

New studies are showing the dawn of a new era in how cancer care teams will go about treating patients with small cell lung cancer with immunotherapy combinations.

The FDA accepts the application of a biosimilar of bevacizumab in the treatment of patients with NSCLC.

Immunotherapy in the neoadjuvant setting shows promise for patients with stage III lung cancer.

Immunotherapy as a frontline treatment for patients with advanced nonsquamous NSCLC is showing potential, but there is still additional testing that needs to be done.

Future treatment for patients with the KRAS G12C mutation in NSCLC shows potential promise, according to a principal investigator studying the AMG 510 inhibitor.

The use of immunotherapy in tandem with chemotherapy is the future of treating patients with NSCLC, according to expert Catherine Shu, MD.

Lung cancer treatments are advancing. With these changes come new complications and questions that nurses will have to address with their patients.

With the emphasis on testing for biomarkers to determine treatment for patients with lung cancer, it's important to make sure the testing will have an impact on clinical decisions.

With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.

New study results show that chemoimmunotherapy combination options provide an overall survival benefit to patients with stage IV nonsquamous NSCLC.

New therapeutic options are emerging for patients with Lung cancer positive for ALK or ROS1.

Looking at biomarkers PD-L1 and TMB in tandem can help predict a patient with NSCLC reaction to immunotherapy.

A closer look at the genealogy of Utah's founders provided one expert with a data mine to help combat lung cancer.

With plenty of data from the CheckMat-227 trial to go through, one expert breaks down the vital data that will directly impact the practice.

At the 2019 World Conference on Lung Cancer, an NSCLC expert weighed in on the usefulness of cell-free DNA-based testing versus traditional tissue testing for genomic sequencing.

While some view immunotherapy as limiting in small-cell lung cancer treatment, one expert believes otherwise.

Throughout all of the cancer landscape, there are racial disparities in the way patients are treated, and for mesothelioma patients, those disparities can make the difference between life and death.

In about 3% to 5% of patients with NSCLC MET alterations are presented that can drastically change a patient's prognosis. Now, an investigational MET inhibitor called tepotinib was granted a breakthrough designation by the FDA, and it may prove beneficial for patients in this space.

While treatment options for lung cancer have vastly improved over the last decade, attitudes toward the disease have actually gotten worse.

Targeted therapies for patients with EGFR-mutated and HER2-positive NSCLC have yet to see widespread success, but these 3 novel therapies, presented at the 2019 World Conference on Lung Cancer, show promise for this patient population.

The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.

Patients with METex14-Mutated NSCLC potentially have a new first-line treatment to look towards as Capmatinib has been granted a breakthrough designation by the FDA.

Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.